Age-related Macular Degeneration (AMD)
Conditions
Keywords
AMD,, brolucizumab,, anti-VEGF switchers,, treatment-naive
Brief summary
This was the cross-sectional study to assess the period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019.
Detailed description
In this cross-sectional study of patients with wet AMD who received ≥1 anti-VEGF injection (excluding brolucizumab), evidence was generated to describe the period prevalence of specific ocular AEs. The study was conducted using the Komodo Healthcare Map, and all results were based on the study period from 01/01/2018 to 12/31/2019. Komodo Healthcare Map data from 01/01/2018 to 12/31/2019 for patients with a diagnosis of wet AMD who were treated with ≥1 anti-VEGF agent (excluding brolucizumab) were included. * Identification period: Patients fulfilling the selection criteria during the period from 01/01/2019 to 12/31/2019 were identified * Index date: 01/01/2019 * Study Period: 01/01/2018 to 12/31/2019 * Pre-index period: 01/01/2018 to 12/31/2018 * Post-index period: 01/01/2019 to 12/31/2019
Interventions
OTHERAflibercept
intravitreal injection
OTHERRanibizumab
intravitreal injection
OTHERBevacizumab
intravitreal injection
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* ≥1 International Classification of Diseases, Clinical Modification-9/10 (ICD-9/10) code for wet AMD in 2019 * ≥1 Healthcare Common Procedure Coding System (HCPCS) code (J code) or National Drug Code (NDC) code for treatment with an anti-VEGF agent (excluding brolucizumab) in 2019 * ≥18 years old in 2019 * ≥2 wet AMD-related office visits in 2019
Exclusion criteria
\- ≥1 HCPCS code (J code) or NDC code for treatment with brolucizumab in 2019
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with Intraocular Inflammation (IOI) Adverse events (AEs) who were treated with anti-VEGF agents | earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 | Period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019 was assessed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gender information | earliest claim of anti-VEGF injection (excluding brolucizumab) over a one-year period from 01/012019 to 31/12/2019 | Gender information was reported |
| Number of patients at various Patient Region | earliest claim of anti-VEGF injection (excluding brolucizumab) over a one-year period from 01/012019 to 31/12/2019 | Patient regions: Northeast, Midwest, South, West, Unknown |
| Number of patients with Insurance type | earliest claim of anti-VEGF injection (excluding brolucizumab) over a one-year period from 01/012019 to 31/12/2019 | Private, Medicare, Medicare Advantage, Medicaid, Other |
| Number of patients with Laterality of wet Age-related macular degeneration (AMD) | Index date (defined as the date of first injection - 01/01/2019) | Laterality of wet AMD: Unilateral, Bilateral |
| Age | earliest claim of anti-VEGF injection (excluding brolucizumab) over a one-year period from 01/012019 to 31/12/2019 | Age information was reported |
| Number of patient eyes treated with anti-VEGF agent | Index date (defined as the date of first injection - 01/01/2019) | The following types were included OD \[eye, right\], OS \[eye, left\], Unspecified |
| Number of anti-VEGF injections | over a one-year period from 01/012019 to 31/12/2019 | Anti-VEGF utilization in patients with wet AMD who were treated with anti-VEGF agents (excluding brolucizumab) over a one-year period was assessed. Measured at the patient level and patient-eye level. |
| Number of patients with other ocular AEs in patients with wet AMD who were treated with anti-VEGF agents (excluding brolucizumab) | over a one-year period from 01/012019 to 31/12/2019 | The following types were included: 1. Key ocular AEs 2. IOI events 3. RVO events 4. Unspecified RO 5. Autoimmune disorders (systemic lupus erythematosus \[SLE\], Behcet's disease, sarcoidosis, VKH disease, HLA-B27 syndromes, Drug hypersensitivity) 6. RV without RO (RAO and/or RVO) |
| Number of patient eyes with the Provider specialty on date of first anti-VEGF injection | earliest claim of anti-VEGF injection (excluding brolucizumab) over a one-year period from 01/012019 to 31/12/2019 | The following types were included: Retina specialist, General ophthalmologist |
Countries
United States
Outcome results
None listed